Oncology

Biosimilars Check-In: Canada Approves Third Etanercept; Prestige Withdraws Trastuzumab Application

September 29th 2022

By Skylar Jeremias

Article

Health Canada approved Lupin Limited’s Rymti, the third etanercept biosimilar to be granted regulatory approval in the country. Meanwhile, Prestige Biopharma announced that it withdrew its European application for its trastuzumab biosimilar.

Coherus Rep Discusses Interchangeable Ophthalmology Biosimilar, Previews Onpro Competitor

September 28th 2022

By Skylar Jeremias

Video

Part 5 available now! Paul Reider, MBA, chief commercial officer at Coherus Biosciences, chronicles why Coherus got an interchangeable designation for its ophthalmology biosimilar, how it plans to set its adalimumab biosimilar apart from the rest, and when the pegfilgrastim market could see a competitor for Neulasta Onpro.

Dr Ivo Abraham Column: When More May Yield Less—Price Erosion of Biosimilars Following US Market Entry

September 26th 2022

By Ivo Abraham, PhD

Article

Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, chronicles how drug prices as a result of biosimilar competition has evolved over time and what factors may contribute the most to price erosion.

Oncology, Ophthalmology Biosimilars Progress in Europe

September 19th 2022

By Skylar Jeremias

Article

As the United Kingdom adds another oncology biosimilar to its collection, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for another ranibizumab candidate.

FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar

September 6th 2022

By Skylar Jeremias

Article

Fresenius Kabi announced the FDA approval of its pegfilgrastim biosimilar referencing Neulasta, making it the sixth pegfilgrastim biosimilar to be approved in the United States.

EC Grants Celltrion Avastin Biosimilar Marketing Authorization

August 20th 2022

By Skylar Jeremias

Article

The European Commission (EC) authorized Celltrion Healthcare’s bevacizumab biosimilar referencing Avastin for marketing across the European Union, making it the seventh bevacizumab biosimilar to be approved in the region.

Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition

August 7th 2022

By Skylar Jeremias

Podcast

On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.

Biosimilars Oncology Roundup: July 2022

August 1st 2022

By Skylar Jeremias

Article

Trials for denosumab biosimilars are ramping up and researchers are concerned whether patients with cancer switching to biosimilars have been adequately informed beforehand.

Deal Would Have Teva Pay $4.25 Billion to Settle US Opioid Lawsuits

July 27th 2022

By The Center for Biosimilars

Article

The deal follows a string of trials and settlements totaling $550 million in separate cases around the country.

Companies Clinch Deals for Global Biosimilar Commercialization

July 26th 2022

By Skylar Jeremias

Article

Prestige Biopharma and Intas Pharmaceuticals join forces to partner on a bevacizumab biosimilar for multiple countries, and Hikma Pharmaceuticals makes a deal with Celltrion Healthcare for the commercialization of an adalimumab biosimilar.